Comparison of expression of the activating Fc receptors CD32A and CD16 on mature immune cells in bone marrow of unaffected individuals versus those with AML revealed significant downregulation of the activating receptor CD32A on classical (CD14+CD16−; P = 0.02), immature (CD14+CD16+; P = 0.02) and nonclassical (CD14−CD16+; P < 0.0001) monocytes (Fig. 3b) as well as downregulation of activating receptor CD16 on CD56dim NK cells (P = 0.0002) in patients with AML (Fig. 3c). This evidence concerns the gene FCGR2A and acute myeloid leukemia.